-
1 Comment
Circassia Group Plc is currently in a long term uptrend where the price is trading 8.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Finally, its free cash flow grew by 34.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Circassia Group Plc gets an overall score of 3/5.
Exchange | F |
---|---|
ISIN | GB00BJVD3B28 |
Sector | Healthcare |
Industry | Medical Devices |
CurrencyCode | EUR |
Market Cap | 304M |
---|---|
PE Ratio | 69.5 |
Beta | 0.77 |
Dividend Yield | 2.1% |
Target Price | None |
NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled Nitric Oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 82C.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025